Background: Alzheimer’s disease (AD) patients often express significant behavioral symptoms: for this reason, accessible related biomarkers could be very useful. Neuroinflammation is a key pathogenic process in both AD and delirium (DEL), a clinical condition with behavioral symptoms resembling those of AD. Methods: A total of n = 30 AD patients were recruited together with n = 30 DEL patients and n = 15 healthy controls (CTRL). Serum diazepam binding inhibitor (DBI), IL-17, IL-6, and TNF-α were assessed by ELISA. Results: DBI serum levels were increased in AD patients with respect to CTRL (+ 81%), while DEL values were 70% higher than AD. IL-17 was increased in DEL with respect to CTRL (+ 146%), while AD showed dispersed values and failed to reach significant differences. On the other hand, IL-6 showed a more robust increase in DEL with respect to the other two groups (+ 185% and + 205% vs. CTRL and AD, respectively), and TNF-α failed to show any change. Conclusions: DBI may be a very promising candidate for AD, perhaps marking psychomotor DEL-like symptoms, in view of developing future helping tool for practicing physicians. Furthermore, DBI rise in DEL offers novel cues for a better comprehension of the pathogenesis of this potentially fatal condition.

Conti, E., Andreoni, S., Tomaselli, D., Storti, B., Brovelli, F., Acampora, R., et al. (2021). Serum DBI and biomarkers of neuroinflammation in Alzheimer's disease and delirium. NEUROLOGICAL SCIENCES, 42(3), 1003-1007 [10.1007/s10072-020-04608-x].

Serum DBI and biomarkers of neuroinflammation in Alzheimer's disease and delirium

Conti, Elisa
Primo
;
Andreoni, Simona;Storti, Benedetta;Brovelli, Francesco;Acampora, Roberto;Da Re, Fulvio;Appollonio, Ildebrando;Ferrarese, Carlo;Tremolizzo, Lucio
Ultimo
2021

Abstract

Background: Alzheimer’s disease (AD) patients often express significant behavioral symptoms: for this reason, accessible related biomarkers could be very useful. Neuroinflammation is a key pathogenic process in both AD and delirium (DEL), a clinical condition with behavioral symptoms resembling those of AD. Methods: A total of n = 30 AD patients were recruited together with n = 30 DEL patients and n = 15 healthy controls (CTRL). Serum diazepam binding inhibitor (DBI), IL-17, IL-6, and TNF-α were assessed by ELISA. Results: DBI serum levels were increased in AD patients with respect to CTRL (+ 81%), while DEL values were 70% higher than AD. IL-17 was increased in DEL with respect to CTRL (+ 146%), while AD showed dispersed values and failed to reach significant differences. On the other hand, IL-6 showed a more robust increase in DEL with respect to the other two groups (+ 185% and + 205% vs. CTRL and AD, respectively), and TNF-α failed to show any change. Conclusions: DBI may be a very promising candidate for AD, perhaps marking psychomotor DEL-like symptoms, in view of developing future helping tool for practicing physicians. Furthermore, DBI rise in DEL offers novel cues for a better comprehension of the pathogenesis of this potentially fatal condition.
Articolo in rivista - Articolo scientifico
Alzheimer’s disease; Cytokines; Delirium; Diazepam binding inhibitor; Monocytes; Serum;
English
23-lug-2020
2021
42
3
1003
1007
none
Conti, E., Andreoni, S., Tomaselli, D., Storti, B., Brovelli, F., Acampora, R., et al. (2021). Serum DBI and biomarkers of neuroinflammation in Alzheimer's disease and delirium. NEUROLOGICAL SCIENCES, 42(3), 1003-1007 [10.1007/s10072-020-04608-x].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/280383
Citazioni
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 13
Social impact